Subcutaneous rituximab induction followed by short rituximab maintenance to improve progression-free survival in patients with low-tumor burden follicular lymphoma: Final results of FLIRT phase III trial, a LYSA study.

被引：0

作者：

Cartron, Guillaume

Bachy, Emmanuel

Tilly, Herve

Daguindau, Nicolas

Pica, Gian Matteo

Bijou, Fontanet

Mounier, Christiane

Clavert, Aline

Damaj, Gandhi Laurent

Slama, Borhane

Casasnovas, Olivier

Houot, Roch

Bouabdallah, Krimo

Sibon, David

Fitoussi, Olivier

Morineau, Nadine

Morschhauser, Franck

Xerri, Luc

Tarte, Karin

Pranger, Delphine

机构：

[1] CHU Montpellier, Montpellier, France

[2] Ctr Hospitalier Lyon Sud, Lyon, France

[3] Ctr Henri Becquerel, Rouen, France

[4] CH Annecy Genevois, Annecy, France

[5] CH Chambery, Chambery, France

[6] Inst Bergoni, Bordeaux, France

[7] Inst Cancerol Lucien Neuwirth, St Priest En Jarez, France

[8] CHU Angers, Angers, France

[9] CHU Amiens, Amiens, France

[10] CH Avignon, Avignon, France

[11] CHU Dijon, Dijon, France

[12] Hop Pontchaillou CHU Rennes, Rennes, France

[13] CHU Bordeaux, Bordeaux, France

[14] Hop Necker Enfants Malad, Paris, France

[15] Polyclin Bordeaux Nord, Bordeaux, France

[16] CH Roche Yon, La Roche Sur Yon, France

[17] CHU Lille, Lille, France

[18] Inst Paoli Calmettes, Marseille, France

[19] CHU Rennes, Rennes, France

[20] CH Charleroi, Charleroi, Belgium

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 16期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

7512

引用

页数：1

共 32 条

[31] High Dose Imatinib Induction Therapy (800 mg/day, 6 Months) In Pre-Treated Chronic Phase CML Patients Improves Cytogenetic and Molecular Responses but Does Not Improve Overall and Progression Free Survival - Final Results of the CELSG Phase III CML11 "ISTAHIT" Trial
Perzeri, Andreas L.
Fong, Dominic
Lion, Thomas
Dyagil, Irina
Masliak, Zvenyslava
Bogdanovic, Andrija
Griskevicius, Laimonas
Lejniece, Sandra
Goranov, Stefan
Gercheva, Liana
Stojanovic, Aleksandar
Peytchev, Dontcho
Tzetkov, Nikolay
Griniute, Rasa
Oucheva, Radka
Grubinger, Thomas
Kwakkelstein, Marthin
Rancati, Francesca
Gastl, Guenther A.
Wolf, Dominik
BLOOD, 2010, 116 (21) : 934 - 935
[32] Extended Follow up of the CLL8 Protocol, a Randomized Phase-III Trial of the German CLL Study Group (GCLLSG) Comparing Fludarabine and Cyclophosphamide (FC) to FC Plus Rituximab (FCR) for Previously Untreated Patients with Chronic Lymphocytic Leukemia (CLL): Results On Survival, Progression-Free Survival, Delayed Neutropenias and Secondary Malignancies Confirm Superiority of the FCR Regimen
Fischer, Kirsten
Bahlo, Jasmin
Fink, Anna-Maria
Busch, Raymonde
Boettcher, Sebastian
Mayer, Jiri
Dreger, Peter
Maurer, Christian
Engelke, Anja
Kneba, Michael
Doehner, Hartmut
Eichhorst, Barbara F.
Wendtner, Clemens-Martin
Stilgenbauer, Stephan
Hallek, Michael
BLOOD, 2012, 120 (21)

← 1 2 3 4 →